NCT01703481 2025-02-03A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Adult Participants With Advanced or Refractory Solid Tumors or LymphomaJanssen Research & Development, LLCPhase 1 Completed188 enrolled